🔎 Trials Near Me

Utama › Limfoma Sel Mantel › Connecticut

Kajian klinikal Limfoma Sel Mantel di Connecticut

6 kajian untuk Limfoma Sel Mantel sedang mencari peserta di lokasi di Connecticut.

Bandar di Connecticut

Teks kajian rasmi (Bahasa Inggeris)

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

  • Smilow Cancer Hospital-Derby Care Center, Derby
  • Smilow Cancer Hospital Care Center-Fairfield, Fairfield
  • Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury
  • dan 10 lagi
Mengambil pesertaFasa 3
Umur 60 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05976763

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  • Yale University Yale Cancer Center, New Haven
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06742996

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • Yale University School of Medicine - Yale Cancer Center, New Haven
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07101328

DALY II USA/ MB-CART2019.1 for DLBCL

  • Yale University, New Haven
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT04792489

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • Yale Cancer Center, New Haven
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Jul 2026 · NCT05131022

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Hartford
  • Massive Bio SYNERGY-AI site, Norwalk
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.